Summary of "Neurologist Reveals How Vitamin D & the Microbiome Is Linked to Sleep Disorders | Dr. Stasha Gominak"

Core ideas

Vitamin D functions as a steroid hormone, not just a simple vitamin. It has wide-ranging, coordinated effects on physiology including sex hormones, thyroid, metabolism, immune function, gene expression, behavior, and seasonal/hibernation-like responses.
Vitamin D status influences sleep by acting on vitamin D receptors in the brainstem and other brain regions that regulate sleep timing and the paralysis of deep sleep.
Vitamin D upregulates choline acetyltransferase (the enzyme that synthesizes acetylcholine). Acetylcholine:
- Supports daytime attention via cortical cholinergic centers.
- Is required in brainstem cholinergic centers to enter deep, paralyzed (restorative) sleep at night.
- Therefore: vitamin D → increased acetylcholine production → effects on both wakefulness and deep sleep attainment.
Gene expression changes in response to vitamin D are dependent on dose and rate-of-rise. Small supplements versus larger or faster repletion produce different genomic responses.
Evolutionary framing: vitamin D can act as a seasonal/hibernation signal. Falling vitamin D may signal “winter,” lowering metabolism and increasing sleep or fat storage through microbiome-mediated pathways.
Microbiome-centered model:
- Loss or dysfunction of the normal microbiome reduces endogenous production of key B-vitamins and other microbial metabolites the host depends on.
- Proposed typical sequence: vitamin D falls → microbiome dysfunction worsens → deficiencies in microbially produced B-vitamins/metabolites → sleep and systemic problems.
B vitamins (particularly pantothenic acid / B5 and the full B-complex) are important because:
- B5 is a precursor for coenzyme A (required for many metabolic pathways, cortisol synthesis, and a role in acetylcholine synthesis).
- The microbiome normally produces many B-vitamins in appropriate ratios and timing; supplementing vitamin D without microbiome restoration can create relative B-vitamin shortages or dose-dependent adverse effects.

Clinical pattern and population-level observations

Many people worldwide have chronically low vitamin D, which corresponds with widespread abnormal sleep study results and rising incidence of sleep disorders, metabolic disease, IBS, autoimmune conditions, obesity, and chronic fatigue.
Diseases that historically appeared in older age are appearing earlier, possibly linked to changes in vitamin D exposure and microbiome disruption.
The microbiome differs along the GI tract (mouth, stomach, small intestine segments, colon). Metabolites produced in different segments have distinct local and systemic effects (for example, effects on enteroendocrine signaling, GLP-1, hunger, and metabolism).
Reintroducing or encouraging the correct microbial community is necessary for long-term restoration of vitamin production and metabolic signaling.

Clinical/phenomenological observations reported by Dr. Gominak

Many patients with sleep disturbances had low vitamin D even in months when sun exposure should be adequate.
Short-term vitamin D supplementation improved sleep and headaches for some patients, but benefits sometimes waned after roughly two years unless the microbiome and B-vitamin status were addressed.
Signs consistent with pantothenic acid (B5) deficiency, described in clinical anecdotes and older experimental diets, include burning hands/feet, neuropathic pain, sleep loss, and gait changes.
High isolated doses of B5 produced acute agitation or daytime restless-legs-like symptoms in multiple patients. Smaller divided doses or full B-complex dosing (e.g., B100) often produced improvement without agitation.
Autoimmune and pain syndromes responded variably; historical literature (1950s–1970s) included trials of pantothenic acid for autoimmune conditions, given its role in coenzyme A and cortisol synthesis.

Practical clinical pathway (method summarized)

Assess
- Obtain patient history focused on sleep patterns, IBS/GI symptoms, neuropathic pain, restless legs, and metabolic issues.
- Measure serum 25(OH)D (vitamin D) and B12 (and other labs as indicated).
Replete vitamin D
- Use D3 under monitoring; measure blood 25(OH)D periodically to guide dosing rather than using fixed amounts.
Support B-vitamin status and the microbiome
- Give a broad/high-dose B-complex (clinically, a “B100” was used) concurrently for weeks–months to support acetylcholine/coenzyme A pathways and help microbiome recovery.
Monitor response and adjust
- Track sleep quality, pain, agitation, restless legs, and GI symptoms.
- If adverse effects appear after starting a specific B dose (e.g., agitation, daytime restless legs), reduce or stop that supplement and adjust (for example, halve the dose or switch to a lower-dose B-complex).
Continue and taper
- Continue supplementation long enough to allow microbiome recovery; taper as symptoms and labs improve. Some patients may need a long-term low-background multivitamin while other deficiencies correct.
Emphasize prevention
- Encourage increased outdoor time, natural sun exposure, and measures that support the microbiome and circadian entrainment.

Practical recommendations and principles

Prefer natural sun exposure and broader outdoor time where possible; multiple wavelengths (not just UVB) have biologic effects.
If supplementing vitamin D, test and monitor 25(OH)D levels periodically and adjust dosing.
When correcting low vitamin D, consider restoring the microbiome and giving a broad B-complex (not single-B supplements) for a prolonged period to reconstitute microbe-derived vitamin production.
Pay attention to clinical symptoms (sleep quality, pain, neuropathic symptoms, agitation, restless legs, burning feet) rather than relying solely on standard blood-reference cutoffs. Blood levels reflect “leftover” after tissue uptake and may be misleading.
Be cautious: vitamins can behave like drugs. Dosing and combinations matter and can cause adverse effects if mishandled or used in isolation.

Important cautions

Single-variable studies and simplistic “one-vitamin-fits-all” thinking miss complex system interactions among vitamins, the microbiome, and physiology.
Blood levels must be interpreted in clinical context: tissue uptake, acute demand, and longitudinal response to supplementation are important.
Individualized monitoring and symptom-tracking are essential. Dosing should be adjusted based on both labs and clinical response.
Reconstituting the microbiome is not a trivial or immediate process; clinical improvement may require weeks to months and careful titration of supplements.

Researchers and sources mentioned

Dr. Stasha Gominak — neurologist (MD from Baylor College of Medicine; neurology residency at Massachusetts General Hospital / Harvard-affiliated). Author of papers and clinical programs on vitamin D, the microbiome, and sleep (including work around “The world epidemic of sleep disorders is linked to vitamin D deficiency” and other publications/presentations).
Walter Stumpf — vitamin D receptor researcher, cited for identifying vitamin D receptors in brainstem, pituitary, stomach, and other tissues and for the concept of vitamin D as a widespread hormonal regulator and “hibernation hormone.”
Historical/older studies referenced:
- 1950s pantothenic acid deficiency experiments (institutionalized subjects/convicts; Iowa State Prison experiments cited).
- Mid-20th century to 1970s literature on pantothenic acid and autoimmune disease.
Recent microbiome literature (circa 2020) showing interactions between vitamin D and the microbiome, plus Dr. Gominak’s own published clinical work (mid-2010s, 2016).

Key takeaways

Vitamin D acts as a hormone with broad regulatory effects, including on sleep via acetylcholine pathways.
The microbiome and microbially produced B-vitamins are central to how vitamin D status impacts sleep and systemic health.
Clinical management of low vitamin D should include monitoring, cautious repletion, concurrent support of B-vitamin status (preferably a full B-complex), and efforts to restore healthy microbiome function, with careful symptom-based dose adjustments.